KunkelRS. Pharmacologic management of migraine. Cleve Clin Q1985; 52: 95–101.
2.
SicuteriF. Prophylactic and therapeutic properties of lysergic acid butanolamide in migraine. Int Arch Allergy1959; 15: 300–7.
3.
GrahamJR. Methysergide for prevention of headache: Experience in five hundred patients over three years. N Engl J Med1964; 270: 67–72.
4.
GrahamJRSubyHILecomptePMSadowskyNL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med1966; 274: 359–68.
5.
DunnJMSiranH. Pleural effusion and fibrosis secondary to Sansert administration. Ann Thorac Surg1973; 15: 295–8.
6.
BanaDSMacnealPSLecomptePMShahYGrahamJR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J1974; 88: 640–55.
7.
KinderCH. Retroperitoneal fibrosis. J R Soc Med1979; 72: 485–6.
8.
KoepLZuidemaGD. The clinical significance of retroperitoneal fibrosis. Surgery1977; 81: 250–7.
9.
BianchineJRMacaraegPVJJr. Serotonin and fibrosis. Arch Intern Med1968; 122: 167–9.
10.
SteckerJRJrRawlsHPDevineCJJr. Retroperitoneal fibrosis and ergot derivatives. J Urol1974; 112: 30–2.
11.
WeissJMHinmanFJr. Reversible retroperitoneal fibrosis and ureteral obstruction associated with ingestion of Sansert. J Urol1966; 95: 771–5.
12.
DolieW. Retroperitoneal fibrosis (Ormond's disease), manifestation of possibly genetically caused, sometimes methysergide induced, multifocal fibrosclerosis (abstract). Internist1969; 10: 245.
13.
Package insert. Sansert (methysergide maleate). East Hanover, NJ: Sandoz Pharmaceuticals Corp., July 1986.
14.
Lepage-SaveryDVallieresA. Ergotamine as a possible cause of retroperitoneal fibrosis. Clin Pharm1982; 1: 179–80.
15.
RobertMDerbandrenghienJPBlampainJPLamyFMeyerPH. Fibrotic processes associated with long-term ergotamine therapy (letter). N Engl J Med1984; 311: 601–2.
16.
DamstrupLJensenTT. Retroperitoneal fibrosis after long-term daily use of ergotamine. Int Urol Nephrol1986; 18: 299–301.
17.
McevoyGK, ed. American Hospital Formulary Service drug information 87. Bethesda, MD: American Society of Hospital Pharmacists, 1987: 620–3.
18.
BowlerJVOrmerodIELeggNJ. Retroperitoneal fibrosis and bromocriptine (letter). Lancet1986; 1: 466.
19.
DemonetJFKostinMDueymesJMIoualalenAMontastrucJLRascolA. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol1986; 9: 200–1.
20.
SchwartzFDDuneaG. Progression of retroperitoneal fibrosis despite cessation of treatment with methysergide. Lancet1966; 30: 955–66.
21.
CastlemanBSculleyREMcNeelyBU. Case records of the Massachusetts General Hospital. N Engl J Med1973; 288: 254–61.
22.
UtzDCRookeEDSpittellJAJrBartholomewLG. Retroperitoneal fibrosis in patients taking methysergide. JAMA1965; 191: 983–5.
23.
CoganEFastrezR. Azathioprine, an alternative treatment for recurrent idiopathic retroperitoneal fibrosis. Arch Intern Med1985; 145: 753–5.
24.
HenriLGroleauM. Retroperitoneal fibrosis after treatment with propranolol (letter). Drug Intell Clin Pharm1981; 15: 696.
25.
DohertyCCMcGeownMGDonaldsonRA. Retroperitoneal fibrosis after treatment with atenolol (letter). Br Med J1978; 2: 1786.
26.
JohnsonJNMcFarlandJ. Retroperitoneal fibrosis associated with atenolol (letter). Br Med J1980; 280: 864.
27.
PierceJRJrTrostleDCWarnerJJ. Propranolol and retroperitoneal fibrosis (letter). Ann Intern Med1981; 95: 244.
28.
McCluskeyDRDonaldsonRAMcGeownMG. Oxprenolol and retroperitoneal fibrosis. Br Med J1980; 281: 1459–60.
29.
ThompsonJJulianDG. Retroperitoneal fibrosis associated with metoprolol. Br Med J1982; 284: 83–4.
30.
LaaksoMArvalaITervoenSSotarautaM. Retroperitoneal fibrosis associated with sotalol. Br Med J1982; 285: 1085–6.
31.
PryorJPCastleWMDukesDCSmithJCWatsonMEWilliamsJL. Do beta-adrenoceptor blocking drugs cause retroperitoneal fibrosis. Br Med J1983; 287: 639–41.
32.
AsburyMJ. Retroperitoneal fibrosis after treatment with atenolol (letter). Br Med J1979; 1: 492.
33.
GavinMJCastleWMCruickshankJMWaycottJA. Retroperitoneal fibrosis associated with atenolol (letter). Br Med J1980; 280: 1227–8.
34.
MitchensonMJ. Retroperitoneal fibrosis associated with metoprolol (letter). Br Med J1982; 284: 347.
35.
BullimoreDW. Retroperitoneal fibrosis associated with metoprolol (letter). Br Med J1982; 284: 664.
36.
HoedlS. Side effects of beta receptor blockers: Review and personal observations (abstract). Hautarzt1985; 36: 549–57.
37.
OsbourneER. Propranolol and Peyronie's disease (letter). Lancet1977; 1: 1111.
38.
CouplandWW. Fibrosing conditions and propranolol. Med J Aust1977; 2: 137.
SpuhlerVZollingerH. Die Chronisch: Interstitialle Nephritis. Z Klin Med1953; 151: 1–51.
41.
LewisCTMollandEAMarshallURTresidderGCBlandyJP. Analgesic abuse, ureteric obstruction, and retroperitoneal fibrosis. Br Med J1975; 2: 76–8.
42.
MacgregorGAJonesMFBarracloughMAWingAJCranstonWI. Ureteric stricture associated with analgesic nephropathy. Br Med J1973; 2: 271–2.
43.
McGregorMSakerBMEnglandEJ. Ureteric stricture associated with analgesic nephropathy. Med J Aust1979; 1: 287–8.
44.
MurrayTGGoldbergM. Analgesic-associated nephropathy in the USA: Epidemiologic, clinical and pathogenetic features. Kidney Int1978; 13: 64–71.
45.
FielSB. Should corticosteroids be used in the treatment of acute, severe asthma? I. A case for the use of corticosteroids in acute, severe asthma. Pharmacotherapy1985; 5: 327–31.
46.
MokJKattanMLevisonH. Should corticosteroids be used in the treatment of acute, severe asthma? II. A case against the use of corticosteroids in acute, severe asthma. Pharmacotherapy1985; 5: 331–5.
47.
BurgePS. The effects of corticosteroids on the immediate asthmatic reaction. Eur J Respir Dis1982; 122 (suppl): 163–6.
48.
BrittonMGCollinsJVBrownDFairhurstNPALambertRG. High-dose corticosteroids in severe acute asthma. Br Med J1976; 2: 73–4.
49.
FantaCHRossingTHMcFaddenER. Glucocorticoids in acute asthma. A critical controlled trial. Am J Med1983; 74: 845–51.
50.
McFaddenERKiserRDegrootWJHolmesBKikerRViserG. A controlled study of the effects of single doses of hydrocortisone on the resolution of acute attacks of asthma. Am J Med1976; 60: 52–9.
51.
SzczeklikANizankowskaECzerniawska-MysikGSekS. Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol1985; 76: 530–6.
52.
HaskellRJWongBMHansenJE. A double-blind, randomized clinical trial of methylprednisolone in status asthmaticus. Arch Intern Med1983; 143: 1324–7.
53.
HarfiHHanissianASCrawfordLV. Treatment of status asthmaticus in children with high doses and conventional doses of methylprednisolone. Pediatrics1978; 61: 829–31.
54.
LittenbergBGluckEH. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. N Engl J Med1986; 314: 150–2.
55.
MattoliSRosatiGMormileFCiappiG. The immediate and short-term effects of corticosteroids on cholinergic hyperreactivity and pulmonary function in subjects with well-controlled asthma. J Allergy Clin Immunol1985; 76: 214–22.
56.
KrouseHASantiagoSMKlaustermeyerWB. Intravenously given methylprednisolone in refractory asthma. West J Med1980; 132: 106–10.
57.
AhmedTKingMMKrainsonJP. Modification of airway histamine receptor function with methylprednisolone succinate. J Allergy Clin Immunol1983; 71: 224–9.
58.
SueMAKwongFKKlaustermeyerWB. A comparison of intravenous hydrocortisone, methylprednisolone, and dexamethasone in acute bronchial asthma. Ann Allergy1986; 56: 406–9.
59.
ChernowBVernoskiBKZalogaGP. Dexamethasone causes less steroid-induced alkemia than methylprednisolone or hydrocortisone. Crit Care Med1984; 12: 384–6.
60.
BaumgartnerTGLaskinJLHarmanE. Suspected anaphylaxis from methylprednisolone injection: Case report and literature review. Am J IV Ther Clin Nutr1983; 10: 44–54.
61.
HarrisonBDWHartGJAliNJ. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet1986; 1: 181–4.
62.
StorrJBarryWBarrellE. Effect of a single oral dose of prednisolone in acute childhood asthma. Lancet1987; 1: 879–81.
63.
Ellul-MicallefR. The acute effects of corticosteroids in bronchial asthma. Eur J Respir Dis1982; 122 (suppl): 118–25.
64.
LeeFHViscontiJA, eds. American druggist blue book 1987–88. New York: The Hearst Corporation.
65.
FosterDW. Diabetes mellitus. In: PetersdorfRGAdamsRDBraunwaldE, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1983: 661–79.
66.
BrownleeMCeramiA. The biochemistry of the complications of diabetes mellitus. Ann Rev Biochem1981; 50: 385–432.
67.
WardJD. Conference report: The polyol pathway and complications of diabetes. Br J Clin Pract1986; 40: 118–22.
68.
CoganDGKinoshitaJHKadorPF. Aldose reductase and complications of diabetes. Ann Intern Med1984; 101: 82–91.
69.
GreeneDALattimerSASimaAAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med1987; 316: 599–606.
70.
PittsNEGundersonKMehtaDJ. Aldose reductase inhibitors in clinical practice: Preliminary studies on diabetic neuropathy and retinopathy. Drugs1986; 32: 30–5.
71.
VasJG CunhaMotaCCLeiteECAbreuJRRausMA. Effect of sorbinil on blood-retinal barrier in early diabetic retinopathy. Diabetes1986; 35: 574–8.
72.
ChristensenJEJVarnekLGregersenG. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: A double-blind study. Acta Neurol Scand1985; 71: 164–7.
73.
JaspanJBTowleLMaselliRHeroldK. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism1986; 35 (suppl 1): 83–92.
74.
JaspanJHeroldKMaselliR. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: Relief of pain and improved somatic and autonomic nerve function. Lancet1983; 2: 758–62.
75.
JudzewitschRGJaspanJBPolonskyKS. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med1983; 308: 119–25.
76.
YoungRJEwingDJClarkeBF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes1983; 32: 938–42.
77.
RaskinPRosenstockJChallisP. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clin Pharmacol Ther1985; 38: 625–30.
78.
KoglinLKincaidJFinebergN. The aldose reductase inhibitor tolrestat increases peripheral nerve conduction velocities and decreases neuropathic pain in patients with symptomatic peripheral diabetic neuropathy (abstract). Diabetes1986; 35 (suppl 1): 462.
79.
KoglinLClarkeCRuderSMullaneJF. The results of the long-term open-label administration of Alredase in the treatment of diabetic neuropathy (abstract). Diabetes1985; 34 (suppl 1): 767.
80.
ForrestRD. Early history of wound treatment. J R Soc Med1982; 75: 198–205.
81.
ForrestRD. Development of wound therapy from the dark ages to the present. J R Soc Med1982; 75: 268–73.
82.
ChirifeJScarmatoGHerszageL. Scientific basis for use of granulated sugar in treatment of infected wounds (letter). Lancet1982; 1: 560.
83.
GordonHMiddletonKSealD. Sugar and wound healing (letter). Lancet1985; 2: 663–4.
84.
ChirifeJHerszageLJosephA. In-vitro study of bacterial growth inhibition in concentrated sugar solutions: Microbiological basis for the use of sugar in treating infected wounds. Antimicrob Agents Chemother1983; 23: 766–73.
85.
KnutsonRAMerbitzLACreekmoreMA. Use of sugar and povidone-iodine to enhance wound healing: Five years' experience. South Med J1981; 74: 1329–35.
86.
Sugar sweetens the lot of patients with bedsores. JAMA1973; 223: 122.
87.
ThomlinsonRH. Kitchen remedy for necrotic malignant breast ulcers (letter). Lancet1980; 2: 707.
88.
QuatraroAMineiADonzellaC. Sugar and wound healing (letter). Lancet1985; 2: 664.
89.
TrouilletJLFagonJYDomartY. Use of granulated sugar in treatment of open mediastinitis after cardiac surgery. Lancet1985; 2: 180–4.
90.
ParishLCCollinsE. Decubitus ulcers: A comparative study. Cutis1979; 23: 106–10.
91.
DebureAGachotBLacourB. Acute renal failure after use of granulated sugar in deep infected wound (letter). Lancet1987; 1: 1034–5.
92.
AddisonMKWalerspielJN. Sugar and wound healing (letter). Lancet1985; 2: 665.
93.
GlickPLGuglielmoBJTranbaughRF. Iodine toxicity in a patient treated by continuous povidone-iodine mediastinal irrigation. Ann Thorac Surg1985; 39: 478–80.
